Loading…
Decision Guide · the metric
GPO decks call it NCR. Practice owners call it “are we underwater.” Same number: what you collected for the drug minus what the drug cost you. Here is the definition, the formula, and a worked example that recomputes from each quarter’s CMS file.
NCR = drug reimbursement collected − drug acquisition cost (per dose, per drug, or per period — administration revenue counted separately). Negative NCR = underwater: the practice subsidizes every administration. NCR is not net collection rate, the revenue-cycle metric that shares its initials.
One 300 mg dose, Medicare math, three acquisition scenarios. Replace the acquisition column with your invoice and this is your number.
| Scenario | Collected (98.4% of allowable) | Acquisition (300 units) | NCR per dose |
|---|---|---|---|
| Acquire at ASP −8% (healthy GPO pricing) | $6,382.81 | $5,629.88 | +$752.94 |
| Acquire at ASP (no spread) | $6,382.81 | $6,119.43 | +$263.38 |
| Acquire at ASP +5% (post-launch squeeze) | $6,382.81 | $6,425.41 | −$42.59 |
Same math, any drug, your numbers: the buy-and-bill calculator. Why the collected figure is 98.4% and not 106%: ASP+6 after sequestration.
Net cost recovery is the dollars a practice actually keeps on a provider-administered drug: total reimbursement collected for the drug minus its acquisition cost. Positive NCR means the drug pays for its own program; negative NCR — 'underwater' in practitioner shorthand — means every administration loses money before staffing and overhead.
They share an acronym and nothing else. Net collection rate is a revenue-cycle metric (collections ÷ collectible revenue, across all services). Net cost recovery is a drug-economics metric (drug reimbursement − drug cost). A practice can run a 98% net collection rate and still have negative net cost recovery on half its biosimilars.
Acquisition above the reimbursement basis. The classic driver is the ASP lag: a payment limit computed from sales two quarters back, while your invoice reflects today. Biosimilar launch waves (ustekinumab in 2026, infliximab for a decade) compress limits faster than acquisition falls — practice surveys have documented products underwater by hundreds of dollars per infusion. Failed coinsurance collection, unbillable waste, and denials finish the job.
Under Medicare math the structural ceiling is the effective add-on — about 4.3% of ASP when coinsurance is fully collected. Operators commonly treat low single digits as workable for Medicare volume and rely on commercial contracts for the real spread. Because commercial rates are contract-specific, an honest benchmark requires your own book — that comparison is precisely what the practice X-Ray runs.
Watch the events that flip NCR negative: quarterly payment-limit changes and each drug’s full pricing history.
Drug economics as of Q3 2026 (Medicare ASP basis)
The practice X-Ray computes NCR per drug from your actual acquisition, payer mix, and 835s — Medicare and the commercial book this page can’t see.